EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials

Vadim Lesan, Timothée Olivier, Vinay Prasad

European Journal of Cancer · 2024-05 · 202 · 114022

DOI: 10.1016/j.ejca.2024.114022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Cancer, 2024-05. Verfasst von Vadim Lesan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Hematology and Oncology Department, Saarland University Hospital, Kirrberger Street 100, 66421, Homburg, Germany. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Arnold Ventures.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kaplan-Meier analysis hinges on the assumption that patients who are censored- lost to follow-up, or only recently enrolled on the study- are no different, on average, than patients who are followed. As such, censoring these patients- omitting their future information and taking the average of those who were followed- should not dramatically change the overall estimate. Yet, in a recent clinical trial, two sets of censoring rules- one favored by trialists and one favored by the US Food and Drug Administration- were applied to a progression-free survival (PFS) estimate. In response, the PFS estimate changed dramatically, increasing the median in the experimental arm from 32 to 43 months, while the control arm was essentially unchanged. In this commentary, we explore the reasons why PFS changed so dramatically. We provide a broad overview of censoring in oncology clinical trials, and suggestions to ensure that PFS is a more reliable endpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansProgression-Free SurvivalRandomized Controlled Trials as TopicKaplan-Meier Estimate

Stichwörter der Autor:innen

CensoringIbrutinibInformative censoringKaplan-MeierMantel cell lymphomaProgression-free survivalVenetoclax

Autor:innen und Institutionen

  • Hematology and Oncology Department, Saarland University Hospital, Kirrberger Street 100, 66421, Homburg, Germany.
  • Oncology Service, Geneva University Hospital, 4 Gabrielle-Perret-Gentil Street, 1205, Geneva, Switzerland.
  • Department of Epidemiology and Biostatistics, University of California San Francisco, 550 16th St, 2nd Fl, San Francisco, CA 94158, USA. Electronic address: vinayak.prasad@ucsf.edu.

Förderung

  • Arnold Ventures

Zitieren

APA

Lesan, V., Olivier, T., & Prasad, V. (2024). Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer, 202, 114022. https://doi.org/10.1016/j.ejca.2024.114022

Vancouver

Lesan V, Olivier T, Prasad V. Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer. 2024;202:114022. doi:10.1016/j.ejca.2024.114022

BibTeX
@article{Lesan2024,
  author = {Lesan, Vadim and Olivier, Timothée and Prasad, Vinay},
  title = {Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials},
  journal = {European Journal of Cancer},
  year = {2024},
  volume = {202},
  pages = {114022},
  doi = {10.1016/j.ejca.2024.114022}
}
Kostenlos starten →